Glimnib M2 Forte Tablet PR is a combination oral antihyperglycemic agent containing Glimepiride 2mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. The prolonged-release formulation ensures a steady plasma concentration, improving patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Glimnib M2 Forte is prescribed as an adjunct to diet and exercise when monotherapy with either agent is insufficient to achieve desired glycemic targets. It is essential to monitor renal function before and during treatment, as Metformin is contraindicated in patients with significant renal impairment due to the risk of lactic acidosis. Common adverse effects may include hypoglycemia, gastrointestinal disturbances such as nausea and diarrhea, and, rarely, allergic reactions. Dose adjustments should be individualized based on clinical response and tolerability. Glimnib M2 Forte Tablet PR should be used under medical supervision with regular monitoring of blood glucose and HbA1c levels to optimize therapeutic outcomes and minimize complications.